AFCR News

Michael Wang, MD., Ph.D., member of AFCR Scientific Advisory Board Excitement spread quickly after a June 14 report that a COVID-19 vaccine developed by Imperial College London in the U.K. will be tested in humans. What excites people is that the vaccine, which…

Michael Wang, MD., Ph.D., member of AFCR Scientific Advisory Board Many people were disappointed by recent high-profile clinical trial results on Remdesivir, the drug that people had put high hopes on as the best candidate for an effective COVID-19 treatment. A report published in…

Michael Wang, MD., Ph.D., member of AFCR Scientific Advisory Board The U.S. death toll has passed the 100,000 mark this week, but effective anti-viral drugs are still not available for the treatment of COVID-19. Rather, many people have been putting their hope on…

Michael Wang, MD., Ph.D., member of AFCR Scientific Advisory Board On February 11, weeks into the COVID-19 outbreak, the novel coronavirus was officially called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as most patients showed mild to severe respiratory illness. Doctors shared the…

Michael Wang, MD., Ph.D., member of AFCR Scientific Advisory Board Early in February, Dr. Sabra Klein, a professor in the Department of Molecular Microbiology and Immunology of the Johns Hopkins Bloomberg School of Public Health, noticed a sex difference in COVID-19 infections based…

Note: This is part two of Dr. Michael Wang’s series that specifically addresses Brain Cancer Treatment during the Coronavirus Pandemic. You can read part one here. Michael Wang, MD., Ph.D., member of AFCR Scientific Advisory Board In addition to surgery, radiation therapy and chemotherapy are…

Michael Wang, MD., Ph.D., member of AFCR Scientific Advisory Board With today being the first day of May, Brain Tumor Awareness Month, I wish to highlight for you a recently produced set of best practices and guidelines pertaining to brain cancer and COVID-19. Glioblastoma,…